Author:
,Malshy Kamil, , ,Eigner Etan, ,Ochsner Anna, ,Morgan John, , ,Nsair Amir, ,Golijanin Borivoj, , ,Mullerad Michael,
Abstract
Objectives: This study aims to investigate the efficacy and outcomes of transurethral resection of the prostate (TURP) in the context of younger male patients. Methods: Males aged ≤55 who underwent TURP at Rambam Health Care Campus from January 2011 to August 2023 were retrospectively reviewed. Clinicodemographic characteristics, indications for surgery, uroflowmetry, pressure-flow study, and early and late postoperative outcomes were collected. Patients with urethral or bladder abnormalities were excluded. Chi-square and Fisher’s exact tests were employed for bivariate analysis. Results: Inclusion criteria were met by 58 men who underwent TURP at a median age of 52 years (interquartile range [IQR] 49.5–54). Median prostate size was 35 mL (24.5–56), with median prostate-specific antigen of 1.4 ng/mL (0.65–3.1). A total of 60% of patients used α-blockers, and 19% used 5α-reductase inhibitors pre-surgery. Overall, 54 (93.1%) had severe lower urinary tract symptoms (LUTS), with 34 (59%) being predominantly emptying and 20 (35%) storage. Most surgeries were performed for refractory LUTS in 38 (66%), followed by urinary retention in 16 (28%). At 6 weeks, 57 (98%) patients were catheter-free. The maximum flow rate and residual volume showed significant improvement from 9 mL/s to 21 mL/s (P=0.01), and from 171 mL to 61 mL (P=0.006), respectively. Pathology revealed benign prostatic hyperplasia in 53 (91.4%), and inflammation in 5 (8.5%). A total of 13 auxiliary procedures were required in 12 patients (20.7%) during follow-up: 7 transurethral bladder neck incisions, 3 re-TURP, 1 meatus widening, and 1 patient required artificial urinary sphincter implantation followed by simple cystectomy for end-stage bladder. Conclusions: In young men, TURP showed short-term gains in flowmetry and catheter removal rates, but a sustained need for subsequent procedures in the long run. In this unique population, patients should be carefully selected, and alternative, less aggressive, interventions should be considered.
Publisher
Rambam Health Corporation
Reference27 articles.
1. The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis;Lee;Sci Rep,2017
2. 2. Pavelić J, Zeljko Z. [Prostate gland-transition zone lesions. Etiology, growth regulation, growth factors, genetic changes]. Lijec Vjesn 2002;124:211-19. [Article in Croatian] Abstract available at: https://pubmed.ncbi.nlm.nih.gov/19658339/ (accessed April 1, 2024).
3. 3. Ng M, Leslie SW, Baradhi KM. Benign Prostatic Hyperplasia. Treasure Island, FL: StatPearls Publishing; 2024. Available at: https://www.ncbi.nlm.nih. gov/books/NBK558920/ (accessed April 1, 2024).
4. Benign prostatic hyperplasia burden comparison between China and United States based on the Global Burden of Disease Study 2019;Liu;World J Urol,2023
5. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia;Lokeshwar;Transl Androl Urol,2019